Lymphoma Archives

A Small Case Series of Intravascular Large B-Cell Lymphoma with Unexpected Findings: Subset of Cases with Concomitant Extravascular Central Nervous System (CNS) Involvement Mimicking Primary CNS Lymphoma

2021-02-12T01:10:12-08:00April 17th, 2017|2017 Publications, Publications|

Breast Implant-Associated Anaplastic Large Cell Lymphoma: Two Distinct Clinicopathological Variants with Different Outcomes

2021-02-12T22:19:56-08:00February 1st, 2016|2016 Publications, Publications|

Discordant Lymphoma Consisting of Mediastinal Large B-Cell Lymphoma and Nodular Sclerosis Hodgkin Lymphoma in the Right Supraclavicular Lymph Nodes: A Case Report

2021-02-12T22:24:11-08:00December 29th, 2015|Archived Publications, Publications|

Molecular Genetic Data Favoring a Sequential Clonal Transformation of a Large B Cell Lymphoma into an Anaplastic Large T Cell Lymphoma, ALK-Negative

2021-02-12T20:48:04-08:00December 1st, 2015|Archived Publications, Publications|

Immunoblastic Follicular Lymphoma: A Very Unusual Transformation of Low-Grade Follicular Lymphoma

2021-02-13T00:46:19-08:00August 13th, 2014|Archived Publications, Publications|

Hydroa Vacciniforme-like Lymphoma: A Chronic EBV+ Lymphoproliferative Disorder with Risk to Develop a Systemic Lymphoma

2021-02-18T21:10:55-08:00October 31st, 2013|Archived Publications, Publications|

Paediatric and Adolescent Elevated Conjunctival Lesions in the Plical Area: Lymphoma or Reactive Lymphoid Hyperplasia?

2021-02-18T21:14:44-08:00October 25th, 2013|Archived Publications, Publications|

Molecular Diagnostics of Hematologic Malignancies

2021-02-18T22:44:51-08:00September 2nd, 2009|Archived Publications, Publications|

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A Small Case Series of Intravascular Large B-Cell Lymphoma with Unexpected Findings: Subset of Cases with Concomitant Extravascular Central Nervous System (CNS) Involvement Mimicking Primary CNS Lymphoma

Breast Implant-Associated Anaplastic Large Cell Lymphoma: Two Distinct Clinicopathological Variants with Different Outcomes

Discordant Lymphoma Consisting of Mediastinal Large B-Cell Lymphoma and Nodular Sclerosis Hodgkin Lymphoma in the Right Supraclavicular Lymph Nodes: A Case Report

Molecular Genetic Data Favoring a Sequential Clonal Transformation of a Large B Cell Lymphoma into an Anaplastic Large T Cell Lymphoma, ALK-Negative

Immunoblastic Follicular Lymphoma: A Very Unusual Transformation of Low-Grade Follicular Lymphoma

Hydroa Vacciniforme-like Lymphoma: A Chronic EBV+ Lymphoproliferative Disorder with Risk to Develop a Systemic Lymphoma

Paediatric and Adolescent Elevated Conjunctival Lesions in the Plical Area: Lymphoma or Reactive Lymphoid Hyperplasia?

Molecular Diagnostics of Hematologic Malignancies

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.